Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
Invesco Ltd. has filed an amended Schedule 13G reporting a passive ownership stake in BioLife Solutions Inc. common stock. Invesco may be deemed to beneficially own 3,932,191 shares, representing 8.2% of the outstanding common stock, held of record by its advisory clients.
Invesco reports sole voting power over 3,607,451 shares and sole dispositive power over all 3,932,191 shares, with no shared voting or dispositive power. The filing identifies Invesco Advisers, Inc. and Invesco Capital Management LLC as relevant subsidiaries, and notes that no individual has more than a 5% economic interest.
Invesco certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of BioLife Solutions.
BioLife Solutions, Inc. furnished a current report to disclose that on January 12, 2026 it issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1, and the company states that this revenue information and the exhibit are being furnished, not filed, so they are not subject to certain liability provisions and are not automatically incorporated into other securities law filings.
BioLife Solutions, Inc. reports that its Chief Quality and Operations Officer, Karen Foster, has decided to retire. She provided notice of her decision on January 8, 2026, and her retirement will be effective March 31, 2026. The company states that her decision to retire is not due to any disagreement with BioLife Solutions on operations, policies, or practices. The company also expresses appreciation for her service and extends best wishes for her retirement.
BioLife Solutions Chief Financial Officer Troy Wichterman reported selling 990 shares of common stock on 01/06/2026 at $25.59 per share. Following this sale, he beneficially owned 150,746 shares.
The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 01/03/2023 to satisfy tax withholding obligations arising from the vesting of restricted stock, indicating it was linked to equity compensation rather than a discretionary open-market exit.
BioLife Solutions Inc. executive Karen A. Foster, Chief Quality and Operations Officer, reported a small automatic sale of company stock. On 01/06/2026, she sold 335 shares of BioLife Solutions common stock at a price of $25.59 per share. After this transaction, she beneficially owned 191,984 shares of common stock directly. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan that became effective on 01/03/2023 and was used to cover tax withholding obligations tied to the vesting of restricted stock.
BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a small sale of company stock. On 01/06/2026, she sold 241 shares of Common Stock at a price of $25.59 per share, leaving her with 75,765 shares owned directly after the transaction.
According to the footnote, this sale was made under a Rule 10b5-1(c) trading plan that was adopted effective 01-03-2023. The filing explains that the trade was executed to satisfy tax withholding obligations related to the vesting of restricted stock rather than as a discretionary open-market sale.
BioLife Solutions executive Aby J. Mathew reported a small insider sale of company stock. On 01/06/2026, the EVP & Chief Scientific Officer sold 405 shares of BioLife Solutions common stock at a price of $25.59 per share. After this transaction, he directly held 349,350 shares of the company’s common stock.
The sale was made under a pre-arranged Rule 10b5-1(c) trading plan that became effective on 01/03/2023, and was carried out to satisfy tax withholding obligations arising from the vesting of restricted stock.
BioLife Solutions' Chief Marketing Officer reported a small insider sale of company stock. On 01/06/2026, Todd Berard sold 344 shares of BioLife Solutions common stock at a price of $25.59 per share, leaving him with 132,564 shares beneficially owned directly after the transaction.
According to the disclosure, this sale was made under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 01/03/2023 and was executed to satisfy tax withholding obligations related to the vesting of restricted stock. This indicates the transaction was part of tax and compensation administration rather than a discretionary open-market sale.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,180,824 shares of BioLife Solutions Inc. common stock, representing 10.8% of the class as of December 31, 2025. The firm has sole power to vote and dispose of all reported shares, with no shared voting or dispositive power.
The filer is classified as an investment adviser and states that the shares were acquired and are held in the ordinary course of business. It also certifies that the holdings are not intended to change or influence control of BioLife Solutions and expressly denies being the beneficial owner of the securities beyond what is required for reporting.
BioLife Solutions Inc. executive vice president and chief scientific officer Aby J. Mathew reported a small insider sale of company stock. On 12/09/2025, he sold 631 shares of common stock at $25.13 per share. After this transaction, he directly owns 349,755 shares of BioLife Solutions common stock.
The filing states that this sale was executed under a pre-arranged Rule 10b5-1(c) trading plan, which was adopted effective 03-08-2024. The purpose of the plan was to sell shares to cover tax withholding obligations arising from the vesting of restricted stock, indicating this was an automated, tax-related transaction rather than a discretionary open-market sale.